Indledning Inden for onkologi er immunterapi dukket op som en banebrydende metode, der udnytter kroppens immunsystem til at bekæmpe ondartede tumorer. Der er mange immunterapeutiske tilgange, men kimærisk antigenmodtagelse.
Introduction Cytokine Release Syndrome (CRS) is an immune system overreaction triggered by therapies like immunotherapy or CAR-T cell treatment. It prompts an influx of cytokines, causing symptoms ranging from fever to potentiall..
Patients undergoing outpatient CAR T-cell therapy for cancer must be cared for by a multidisciplinary team that includes nurse coordinators, according to a poster presented at the 49th Annual Oncology Nursing Society Conference. ..
Introduction CAR T cell therapy, an innovative form of immunotherapy, has demonstrated exceptional efficacy in the treatment of specific tumors by leveraging the potency of a patient's own immune system. Recently, scientists have..
Feb 2024: China's pioneering efforts in creating breakthrough cancer therapeutics have gained traction with the introduction of chimeric antigen receptor (CAR)-engineered T-cell (CAR T) therapy for multiple myeloma, a devastatin..
Discover the magic of CAR-T treatment! Read our blog on patient selection for CAR T therapy. Are you the ideal candidate for this innovative cancer treatment? Find out and begin your personalized journey to cancer recovery. He..
The revolutionary CAR T Cell Therapy is changing the scenario of how we deal with cancer, making it more personal and powerful. This latest therapy uses a patient's own immune cells and genetically modifies them to target and des..
Maj 2023: Chimeric antigen receptor (CAR) T-celleterapi er en innovativ udvikling inden for individualiseret cancerterapi. Patientens egne T-celler modificeres genetisk under fremstillingsprocessen for at udtrykke en..
Marts 2023: Det første kapitel af Sam Neills erindringer ville være et enormt chok for en, der ikke havde nogen forudgående viden om det. Det starter sjovt nok: et godt garn om, at hans datter Elena bliver udspurgt om sin fars jo..
Marts 2023: Kort resumé: Formålet med dette kliniske forsøg er at finde ud af, om anti-MESO antigenreceptor CAR T-celleterapi kan bruges til at behandle epitelial ovariecancer, der er vendt tilbage eller holdt op med at reagere på andre.